The 1989 Nobel prize winner in Physiology/Medicine, Prof. Bishop JM, Qu J and others from G.W. Hooper Foundation, University of California at San Francisco, San Francisco, California 94143, USA has published a research paper in the June 2012 issue of J Cell Biol (I.F: >10) stating that “Nucleostemin maintains self-renewal of embryonic stem cells and promotes reprogramming of somatic cells to pluripotency.”
Based on this this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Interleukin-based Anti-Cancer stem cell therapy: Pro-inflammatory cytokine Resistin suppresses the expression of Nucleoplasmin and reprogramming of somatic cells via down regulation of its target gene. This study suggests that Resistin, by suppressing the expression of Nucleoplasmin, it may increase the expression of a number of tumor suppressor genes. Thereby, it may inhibit self-renewal of ESEs. Thus, pharmacological formulations encompassing “Resistin activators” may be used to target cancer stem cells and cure human cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Interleukin-based Anti-Cancer stem cell therapy: Pro-inflammatory cytokine Resistin suppresses the expression of Nucleoplasmin and reprogramming of somatic cells via down regulation of its target gene, 12/October/2014, 6.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
